Article Information
History
- June 3, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Shoya Iwanami1,†,
- Keisuke Ejima2,†,*,
- Kwang Su Kim1,
- Koji Noshita1,
- Yasuhisa Fujita1,
- Taiga Miyazaki3,
- Shigeru Kohno4,
- Yoshitsugu Miyazaki5,
- Shimpei Morimoto6,
- Shinji Nakaoka7,
- Yoshiki Koizumi8,
- Yusuke Asai9,
- Kazuyuki Aihara10,
- Koichi Watashi11,12,13,14,
- Robin N. Thompson15,16,
- Kenji Shibuya17,
- Katsuhito Fujiu18,19,
- Alan S. Perelson20,‡,
- Shingo Iwami1,12,21,22,23,‡,* and
- Takaji Wakita11
- 1Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka, Japan 8190395.
- 2Department of Epidemiology and Biostatistics, Indiana University School of Public Health-Bloomington, IN, USA 47405.
- 3Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan 852-8501.
- 4Nagasaki University, Nagasaki, Japan 852-8521.
- 5Department of chemotherapy & mycoses, and Leprosy Research Ctr., National Institute of Infectious Diseases, Tokyo, Japan 3320012.
- 6Institute of Biomedical Sciences, Nagasaki University, Japan 852-8501
- 7Faculty of Advanced Life Science, Hokkaido University, Sapporo, Japan 060-0808.
- 8National Center for Global Health and Medicine, Tokyo, Japan 1628655.
- 9Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan 162-8655.
- 10International Research Center for Neurointelligence, The University of Tokyo Institutes for Advanced Study, The University of Tokyo, Tokyo, Japan.
- 11Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan 1628640.
- 12MIRAI, JST, Saitama, Japan 3320012.
- 13Department of Applied Biological Science, Tokyo University of Science, Noda, Japan 2788510.
- 14Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan 6068507.
- 15Christ Church, University of Oxford, Oxford OX1 1DP, UK.
- 16Mathematical Institute, University of Oxford, Oxford OX2 6GG, UK.
- 17Institute for Population Health, King’s College London, London SE1 1UL, UK.
- 18Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan 1138655.
- 19Department of Advanced Cardiology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan 1138655.
- 20Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
- 21Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, Kyoto 6068501, Japan.
- 22NEXT-Ganken Program, Japanese Foundation for Cancer Research (JFCR), Tokyo 1358550, Japan.
- 23Science Groove Inc., Fukuoka 8100041, Japan.
- ↵*Correspondence to kejima{at}iu.edu (KE) and siwami{at}kyushu-u.org (SI)
↵† These authors contributed equally to this study.
‡ These authors contributed equally to this study.
Posted June 03, 2020.
Rethinking antiviral effects for COVID-19 in clinical studies: early initiation is key to successful treatment
